NYSE$ABBV
AbbVie Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
AbbVie's financial performance for Q3 2024 reflected revenue growth and strategic acquisitions.
AbbVie reported a 3.8% increase in net revenues for the third quarter of 2024, reaching $14.460 billion. The company's adjusted diluted EPS was $3.00, a 1.7% increase. AbbVie also raised its full-year adjusted diluted EPS guidance and announced a dividend increase.
- AbbVie's third-quarter diluted EPS was $0.88 on a GAAP basis.
- Net revenues reached $14.460 billion, a 3.8% increase.
- The company successfully completed the acquisition of Cerevel.
- AbbVie raised its 2024 adjusted diluted EPS guidance to $10.90 - $10.94.
Headline financials
Revenue & EPS history
AbbVie · Revenue · Quarterly
$14.5B
Revenue by segment
AbbVie · $13.1B total across 6 segments · Q3 2023
- Immunology$6.78B-11.3%51.6%
- Neuroscience$2.04B—15.5%
- Oncology$1.51B-8.4%11.5%
- Aesthetics$1.24B—9.4%
- Other Key Products$963M—7.3%
- Eye Care$605M—4.6%
Forward guidance
AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94.
Tailwinds
- Full-year 2024 adjusted diluted EPS guidance is raised to $10.90 - $10.94.
- The guidance includes an unfavorable impact of $0.64 per share related to acquired IPR&D and milestones expense.
- The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2024.
- Potential IPR&D and milestones expense related to the acquisition of Aliada Therapeutics is also excluded from AbbVie’s 2024 adjusted diluted EPS guidance.
- AbbVie is announcing an increase in the company's quarterly cash dividend from $1.55 per share to $1.64 per share.
Headwinds
- The adjusted diluted EPS guidance includes an unfavorable impact of $0.64 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2024.
- Any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2024 is excluded from the guidance.
- Potential IPR&D and milestones expense related to the acquisition of Aliada Therapeutics is also excluded from AbbVie’s 2024 adjusted diluted EPS guidance.
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
- Challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry are risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.9%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+3.7%
Avg return
30 days after
55%
32 / 58 earnings
Positive
+17.2%
Q3 2015
Best reaction
-10.2%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +5.3% | +10.3% | |
| Q4 2025 | -7.1% | -1.1% | +2.0% | |
| Q3 2025 | -7.1% | -5.0% | -0.2% | |
| Q2 2025 | +1.0% | +1.4% | +8.5% | |
| Q1 2025 | +3.2% | +8.2% | +1.6% | |
| Q4 2024 | +4.7% | +9.2% | +19.0% | |
| Q3 2024 | +7.6% | +5.8% | -3.4% | |
| Q2 2024 | +5.1% | +6.0% | +12.1% | |
| Q1 2024 | -3.4% | -3.3% | -6.1% | |
| Q4 2023 | +2.2% | +4.4% | +6.8% | |
| Q3 2023 | -2.3% | -1.9% | -4.5% | |
| Q2 2023 | +6.3% | +4.7% | +3.4% | |
| Q1 2023 | -6.6% | -6.3% | -15.0% | |
| Q4 2022 | +5.1% | +5.5% | +3.5% | |
| Q3 2022 | -4.6% | -5.9% | +4.0% | |
| Q2 2022 | -6.4% | -5.7% | -8.9% | |
| Q1 2022 | -5.4% | -3.0% | -4.0% | |
| Q4 2021 | +2.7% | +4.0% | +9.9% | |
| Q3 2021 | +4.7% | +7.2% | +6.2% | |
| Q2 2021 | -2.9% | -3.2% | +0.6% | |
| Q1 2021 | +3.4% | +4.4% | +2.1% | |
| Q4 2020 | +4.9% | +3.3% | +3.1% | |
| Q3 2020 | +9.4% | +17.1% | +30.0% | |
| Q2 2020 | -0.1% | -2.9% | -1.9% | |
| Q1 2020 | -0.4% | +3.9% | +12.7% | |
| Q4 2019 | +8.7% | +12.2% | +1.9% | |
| Q3 2019 | +4.3% | +3.2% | +10.3% | |
| Q2 2019 | +0.8% | -0.1% | -1.0% | |
| Q1 2019 | +1.3% | +0.9% | +1.8% | |
| Q4 2018 | -10.2% | -7.9% | -6.8% | |
| Q3 2018 | +3.0% | +8.4% | +17.5% | |
| Q2 2018 | -2.7% | -0.0% | +3.7% | |
| Q1 2018 | +7.5% | +11.1% | +10.0% | |
| Q4 2017 | +12.9% | +3.6% | +9.6% | |
| Q3 2017 | +1.6% | +3.2% | +5.8% | |
| Q2 2017 | -2.5% | -1.4% | +1.0% | |
| Q1 2017 | +1.4% | +2.4% | +1.6% | |
| Q4 2016 | -1.4% | -0.6% | +1.3% | |
| Q3 2016 | -9.2% | -7.6% | -1.5% | |
| Q2 2016 | +3.4% | +2.9% | -0.2% | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | -2.6% | — | — | |
| Q3 2015 | +17.2% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -3.8% | — | — | |
| Q3 2014 | +3.4% | — | — | |
| Q2 2014 | -0.6% | — | — | |
| Q1 2014 | +3.1% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q4 2013 | -2.0% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2012 | -0.0% | — | — | |
| Q2 2013 | +1.9% | — | — | |
| Q4 2012 | -1.5% | — | — | |
| Q1 2012 | -1.5% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro